Clinical Trial

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-11-30; most recent amendment 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2023-03-30
Trial Details
NCT Number NCT05643742
Lead Sponsor CRISPR Therapeutics AG
Conditions B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Large B-cell Lymphoma
Enrollment 120 participants
Start Date 2023-03-10
Primary Completion 2030-01 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2025-11-14